Pikralida is a biotechnology company that integrates research and development of innovative therapies (R&D) with Contract Research Organization (CRO) services.
As a clinical-stage company, we focus on both proprietary drug development and partnered pharmaceutical research, ensuring a diversified approach that drives innovation and commercial potential. Our mission is to build a high-value portfolio of projects, ultimately leading to future licensing or strategic partnerships for global market introduction.
Our flagship development program is centered around PKL-021 (marimastat), a subnanomolar matrix metalloprotease (MMP) inhibitor with broad therapeutic potential. We are advancing a pipeline of novel applications, with initial clinical-stage programs targeting:
🧠 Neuroprotection (stroke) – therapies designed to minimize long-term neurological damage and improve patient outcomes in ischemic stroke and brain injuries.
⚡ Snakebite envenoming – innovative pre-hospital treatment solutions, including an oral therapy designed to improve accessibility and survival rates in snakebite cases.
Beyond these priority projects, Pikralida maintains an expanding pipeline of preclinical and early-stage programs, exploring additional indications such as diabetic retinopathy and other high-impact therapeutic areas.
In addition to our own R&D pipeline, Pikralida operates as a specialized CRO, offering tailored research and development services to biotech and pharmaceutical companies. Our expertise spans across formulation development and pharmaceutical analysis
📍 Founded in Poland | 🌍 Global ambitions | 🔬 Hybrid business model | 📅 Clinical-stage company
🌐 www.pikralida.eu
